Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TCRαβ+ T-cell/CD19+ B-cell Depleted Hematopoietic Grafts and a Reduced Intensity Preparative Conditioning Regimen Containing JSP191 to Achieve Engraftment and Blood Reconstitution in Patients With Fanconi Anemia

Next Previous
X
Search
Trial Profile

TCRαβ+ T-cell/CD19+ B-cell Depleted Hematopoietic Grafts and a Reduced Intensity Preparative Conditioning Regimen Containing JSP191 to Achieve Engraftment and Blood Reconstitution in Patients With Fanconi Anemia

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Feb 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Briquilimab (Primary) ; Antithymocyte globulin; Cyclophosphamide; Fludarabine; Rituximab
  • Indications Fanconi's anaemia
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 15 Mar 2024 According to Jasper Therapeutics media release, data from the study were presented at the 2024 Stanford Medicine Center for Definitive and Curative Medicine Symposium.
    • 15 Mar 2024 Results presented in the Jasper Therapeutics Media Release.
    • 12 Dec 2023 Results (n=3) reporting safety and efficacy data from phase 1b portion of this trial presented at the 65th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top